Transcript
Diabetic Retinopathy Treatment Market Share, Global Trends, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2016
Future Market Insights
www.futuremarketinsights.com
[email protected]
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends. We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC. Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and Retail. We have a global presence with delivery centers across India specializing in providing global research reports and country research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India. We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for our client.
Research Capabilities
Sector Coverage
Customized Research Syndicated Research Investment Research Social Media Research
Automotive and Transportation Electronics, Semiconductor, and ICT Retail and Consumer Products Industrial Automation and Equipment
Customized Research
Subscription Information
Syndicated Research
For detailed subscription information please contact
Investment Research
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Social Media Research
Hari. T (Sr. Manager - Global Business Development)
Email:
[email protected]
Chemicals & Materials Food and Beverages Services and Utilities Energy, Mining, Oil, and Gas
Report Description Report Description Diabetes is a chronic disorder associated with defects in the secretion of insulin from the pancreas or hyperglycemia linked to insulin resistance which ultimately leads to long term multi-organ complications of eye, kidneys, nerves, blood vessels and heart. The most common and severe sight threatening complication of diabetes is Diabetic Retinopathy (DR) with some form of DR present in around 25-33% diabetic persons at any time. It leads to damaging of the blood vessels present in the retina of the eye. As per WHO estimates, DR contributes around 4.8% of blindness globally. In the US, it is the leading cause of vision loss and new-onset of blindness in working adults. At present diabetes effects 336 million people worldwide which are projected to increase by 54% in 2030 and more than 75% among these diabetic for more than 20 years are likely to have some form of diabetic retinopathy. Diabetic Retinopathy Treatment Market: Drivers and Restraints Diabetic Retinopathy affects both type 1 and type 2 diabetic patients and with prolific increase in patient pool for both the indication, the market for diabetic retinopathy holds great hopes. As per WHO, 41 percent of the population with diabetes are elderly hence the growing market for diabetic retinopathy can be attributed to expanding geriatric population size. In addition to this, up-gradation of healthcare infrastructure along with the growing demand for early detection systems are some of the high impact rendering drivers for the DR market. Also the clinical pipeline for DR seems full of promises with lots of drug under umbrella specifically targeting diabetic retinopathy among the diabetic patients.
Report Description Report Description However, a dearth of skilled ophthalmologist combined with poor primary infrastructure and lack of insurance facilities are restraining the growth of global diabetic retinopathy market. Request free sample Report: http://www.futuremarketinsights.com/reports/sample/repgb-1322 Diabetic Retinopathy Treatment Market: Segmentation
Diabetic Retinopathy Treatment market is classified on the basis of Indication, Treatment type, end users and geography. Based on indication, the global diabetic retinopathy marketcan be segmented as follows: • Non-Proliferative Diabetic Retinopathy (NPDR) • Mild • Moderate • Severe
• Proliferative Diabetic Retinopathy (PDR) Based on Treatment type, the global diabetic retinopathy marketcan be segmented as follows: • Anti-Vascular Endothelial Growth Factor (VEGF) drug
Report Description Report Description • Intraocular Steroid Injection • Laser Surgery • Vitrectomy Based on end-user, the global diabetic retinopathy marketcan be segmented as follows: • Hospitals
• Ophthalmic Clinics • Ambulatory Surgical Centers Diabetic Retinopathy Treatment Market: Overview According to WHO estimates, in 2012, 347 million people were suffering from diabetes globally, of which 11% had diabetic retinopathy. This gigantic population size is expected to increase further with a huge CAGR in coming years. Owing to improved infrastructure and awareness among the people especially of emerging markets like China, India and Brazil, there is strong emphasis on the quality of life (QALY) for diabetic patients demanding early detection and treatment of chronic conditions such as Diabetic Retinopathy, the market seems to be agile and open. Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1322 Diabetic Retinopathy triples the chances of vision impairment and is linked to five-fold risk of blindness.
Report Description Report Description However, people suffering from DR can be treated most commonly with laser to prevent visual impairment and blindness. However, there is a need for the development of lowcost, portable and easy to operate laser devices. Thus paying way to address various unmet need in the diabetic retinopathy market which is expected to grow at great pace in the coming 20 years. Diabetic Retinopathy Treatment Market: Region-wise Outlook Region wise, the global diabetic retinopathy treatment marketis classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa.Among all the geographies, North America dominated the market followed by Europe. The factors attributable for North America is having high obesity rates while Europe has large population of baby boomers. Asia is expected to show the booming growth in next five years. Within the Asian region, western pacific region account for greater share of blindness due to DR as compared to South-East Asia. The major factor contributing to the rising share of Diabetic Retinopathy among the rising economies are large pool of patients and rising support and funding provided by the government. Under Rest of the World section Brazil is the largest market of diabetic retinopathy. Browse full report: http://www.futuremarketinsights.com/reports/diabetic-retinopathytreatment-market
Report Description Report Description Diabetic Retinopathy Treatment Market: Key Players The global Diabetic Retinopathy treatment market is dominated by Bayer AG, Pfizer Inc., Hoffmann-La Roche ltd, Regeneron Pharmaceutical Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science Inc., Ampio Pharmaceuticals Inc., etc. Strategic acquisitions, geographic expansion, agreements, new product launches and collaborations are the major adopted strategies by most key players to achieve growth in the global Diabetic Retinopathy.
Thank You!
To know more about us, please visit our website: www.futuremarketinsights.com For sales queries or new topics email us on:
[email protected]
For other queries contact: Mr. Sudip Saha Future Market Insights: 616 Corporate Way, Suite 2-9018, Valley Cottage, NY 10989, United States T: +1-347-918-3531 | D: +1-845-579-5705
